As such, further characterisation of metabolic tissues and the associated β-AR subtypes mediating beneficial effects, as well as understanding the underlying mechanisms of side effects, could lead to the development of a novel class of β-AR agonists to combat obesity. The gene discussed is ADRB2; the disease is obesity due to melanocortin 4 receptor deficiency.